Health claims about cannabidiol products: a retrospective analysis of U.S. Food and Drug Administration warning letters from 2015 to 2019
USA
Jun 23, 2021
Cannabidiol (CBD) products are increasingly available to consumers in the United States and are subject to regulation by the U.S. Food and Drug Administration (FDA). CBD products cannot be marketed as unapproved new drugs with claims of therapeutic benefit. In addition, because CBD is the active ingredient in a FDA-approved CBD product, Epidiolex, CBD cannot be marketed as, or in, food products or dietary supplements. The FDA has issued Warning Letters to promote voluntary regulatory compliance. These letters provide insights as to the types of violations for CBD products detected in the U.S. market.
FSA to review progress on CBD novel food applications
UK
Dec 05, 2024
TSJ authorized the use of cannabis for medicinal, pharmaceutical and industrial purposes
Brazil
Nov 15, 2024
Ministry of Health proposes CBD requirements in food for human consumption
Colombia
Oct 08, 2024
FDA and FTC issue warning letters for marketing imitation food products containing Delta-8 THC
USA
Jul 19, 2024
Costa Rica regulates cannabis and hemp use in food
Costa Rica
Jun 27, 2024
South Korea prohibits THC or CBD in labeling and advertising of food products
South Korea
Jun 18, 2024
Canada proposes amendments to cannabis regulations
Canada
Jun 17, 2024
Hemp seeds authorized for use in foodstuffs
Argentina
Dec 07, 2023
New Online Platform for the Management of Cannabis Derivatives Manufacturing Licenses
Colombia
Nov 09, 2023
The FSA updates recommendations on foods with CBD
UK
Oct 12, 2023
New regulation on medical cannabis and industrial hemp published
Argentina
Aug 08, 2023
Hemp-derived CBD products to be authorized soon
USA
Jul 20, 2023
Hemp seeds and hemp derived products to be regulated soon
Argentina
Jul 18, 2023
MFDS bans 9 substances in food
South Korea
Jun 14, 2023
Prime Minister disagrees with CBD prohibition bill
Czech Republic
May 17, 2023
